Cargando…
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers
Immune checkpoint inhibitors have revolutionized the treatments of lung cancers, and multiple predictive biomarkers alone or in combination help clinicians with the appropriate therapeutic selections. Recently, chemo-immunotherapy has been recommended for treating advanced non-small cell lung cancer...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876253/ https://www.ncbi.nlm.nih.gov/pubmed/33584678 http://dx.doi.org/10.3389/fimmu.2020.607416 |
_version_ | 1783649932551389184 |
---|---|
author | Wang, Guihua Chai, Qin Xiao, Yajie Peng, Wenying Teng, Miao Wang, Jingyi Lin, Hanqing Su, Xiaofan Wu, Lin |
author_facet | Wang, Guihua Chai, Qin Xiao, Yajie Peng, Wenying Teng, Miao Wang, Jingyi Lin, Hanqing Su, Xiaofan Wu, Lin |
author_sort | Wang, Guihua |
collection | PubMed |
description | Immune checkpoint inhibitors have revolutionized the treatments of lung cancers, and multiple predictive biomarkers alone or in combination help clinicians with the appropriate therapeutic selections. Recently, chemo-immunotherapy has been recommended for treating advanced non-small cell lung cancers in patients without driver mutations. However, the clinical relevance of predictive biomarkers and the treatment efficacy of chemo-immunotherapy in large cell lung carcinoma (LCLC) remain unclear. Here, we reported a rare case of LCLC with none driver gene mutations and low values of multiple predictive biomarkers. These biomarkers included a low PD-L1 expression of 5–10%, a low tumor mutational burden (TMB) of 2.5 muts/mb, a low CD8(+) tumor-infiltrating lymphocyte density of 147.91 psc/mm². After one-cycle chemotherapy, the patient progressed rapidly and then was switched to pembrolizumab combining paclitaxel plus cisplatin. Interestingly, he achieved a partial response after two cycles of chemo-immunotherapy, showing multiple lymph nodes obviously shrunk on CT scan, and other clinical symptoms were relieved when compared with the baseline findings. After five cycles of chemo-immunotherapy, this advanced patient still benefited and was changed to maintenance immunotherapy monotherapy. This case suggests that chemo-immunotherapy may provide an effective therapeutic option for those LCLC patients with low values of multiple predictive biomarkers, particularly for those who progressed from first-line classical treatments. |
format | Online Article Text |
id | pubmed-7876253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78762532021-02-12 Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers Wang, Guihua Chai, Qin Xiao, Yajie Peng, Wenying Teng, Miao Wang, Jingyi Lin, Hanqing Su, Xiaofan Wu, Lin Front Immunol Immunology Immune checkpoint inhibitors have revolutionized the treatments of lung cancers, and multiple predictive biomarkers alone or in combination help clinicians with the appropriate therapeutic selections. Recently, chemo-immunotherapy has been recommended for treating advanced non-small cell lung cancers in patients without driver mutations. However, the clinical relevance of predictive biomarkers and the treatment efficacy of chemo-immunotherapy in large cell lung carcinoma (LCLC) remain unclear. Here, we reported a rare case of LCLC with none driver gene mutations and low values of multiple predictive biomarkers. These biomarkers included a low PD-L1 expression of 5–10%, a low tumor mutational burden (TMB) of 2.5 muts/mb, a low CD8(+) tumor-infiltrating lymphocyte density of 147.91 psc/mm². After one-cycle chemotherapy, the patient progressed rapidly and then was switched to pembrolizumab combining paclitaxel plus cisplatin. Interestingly, he achieved a partial response after two cycles of chemo-immunotherapy, showing multiple lymph nodes obviously shrunk on CT scan, and other clinical symptoms were relieved when compared with the baseline findings. After five cycles of chemo-immunotherapy, this advanced patient still benefited and was changed to maintenance immunotherapy monotherapy. This case suggests that chemo-immunotherapy may provide an effective therapeutic option for those LCLC patients with low values of multiple predictive biomarkers, particularly for those who progressed from first-line classical treatments. Frontiers Media S.A. 2021-01-28 /pmc/articles/PMC7876253/ /pubmed/33584678 http://dx.doi.org/10.3389/fimmu.2020.607416 Text en Copyright © 2021 Wang, Chai, Xiao, Peng, Teng, Wang, Lin, Su and Wu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Guihua Chai, Qin Xiao, Yajie Peng, Wenying Teng, Miao Wang, Jingyi Lin, Hanqing Su, Xiaofan Wu, Lin Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers |
title | Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers |
title_full | Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers |
title_fullStr | Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers |
title_full_unstemmed | Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers |
title_short | Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers |
title_sort | case report: therapeutic response to chemo-immunotherapy in an advanced large cell lung carcinoma patient with low values of multiple predictive biomarkers |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876253/ https://www.ncbi.nlm.nih.gov/pubmed/33584678 http://dx.doi.org/10.3389/fimmu.2020.607416 |
work_keys_str_mv | AT wangguihua casereporttherapeuticresponsetochemoimmunotherapyinanadvancedlargecelllungcarcinomapatientwithlowvaluesofmultiplepredictivebiomarkers AT chaiqin casereporttherapeuticresponsetochemoimmunotherapyinanadvancedlargecelllungcarcinomapatientwithlowvaluesofmultiplepredictivebiomarkers AT xiaoyajie casereporttherapeuticresponsetochemoimmunotherapyinanadvancedlargecelllungcarcinomapatientwithlowvaluesofmultiplepredictivebiomarkers AT pengwenying casereporttherapeuticresponsetochemoimmunotherapyinanadvancedlargecelllungcarcinomapatientwithlowvaluesofmultiplepredictivebiomarkers AT tengmiao casereporttherapeuticresponsetochemoimmunotherapyinanadvancedlargecelllungcarcinomapatientwithlowvaluesofmultiplepredictivebiomarkers AT wangjingyi casereporttherapeuticresponsetochemoimmunotherapyinanadvancedlargecelllungcarcinomapatientwithlowvaluesofmultiplepredictivebiomarkers AT linhanqing casereporttherapeuticresponsetochemoimmunotherapyinanadvancedlargecelllungcarcinomapatientwithlowvaluesofmultiplepredictivebiomarkers AT suxiaofan casereporttherapeuticresponsetochemoimmunotherapyinanadvancedlargecelllungcarcinomapatientwithlowvaluesofmultiplepredictivebiomarkers AT wulin casereporttherapeuticresponsetochemoimmunotherapyinanadvancedlargecelllungcarcinomapatientwithlowvaluesofmultiplepredictivebiomarkers |